Canada's Drug Agency Recommends Gazyva for Lupus Nephritis Reimbursement
Canada's Drug Agency (CDA-AMC) has recommended the public reimbursement of Gazyva (obinutuzumab) for adults with active lupus nephritis. This follows Health Canada's authorization earlier in 2026. Lupus nephritis is a severe kidney condition associated with systemic lupus erythematosus (SLE), affecting a significant portion of lupus patients. The recommendation is based on the REGENCY study, which showed that Gazyva, in combination with standard therapy, significantly improves renal response compared to standard therapy alone. 
